Beruflich Dokumente
Kultur Dokumente
80/A, Baroda Street, Mumbai 400009. The SCN was again returned undelivered from both
these address.
5. It was observed from the website of Ministry of Corporate Affairs (MCA) that there is no
change in the registered office address of the company. Thereafter, on January 30, 2014 the
SCN was served on the company by way of affixture at its registered office.
6. An opportunity of personal hearing was granted to the company on September 2, 2015. The
notice to this effect was served on the company on August 22, 2015, by way of affixture at its
registered office. However the company chose not to appear for the personal hearing on the
scheduled date.
7. I note that sufficient opportunities have been granted to the company and it is not keen to
avail the same. I further note that the company has not even filed any written reply/submission
to the SCN. In view of these facts and circumstances, I deem it appropriate to decide the
matter on the basis of material available on record.
8. I note that as on September 22, 2015 the company had not obtained SCORES authentication,
as required under SEBI circular dated August 13, 2012. I further note that as on September 22,
2015 out of nine investor complaints as indicated in SCN, eight investor complaints were
pending against the company for redressal, the details of which are mentioned in the following
Table:
Details of the complaints
Sr.
no.
Complaint
Registration No.
Date
Receipt
of
SEBIP/MH11/9107221/1
30/05/2011
SEBIP/MH11/9115000/1
30/03/2011
SEBIP/MH12/0004638/1
02/05/2012
SEBIP/MH12/0004638/2
SEBIP/MH12/0005190/1
______________________________________________________________________________
In the matter of Stellar Drugs Limited
Page 2 of 3
SEBIP/MH12/0005190/2
Others
21/05/2012
SEBIP/MH13/0001564/1
SEBIP/MH13/0001564/2
20/2/2013
9. I note that the investor complaints are pending unresolved since the year 2011. In addition to
the obligations under the provisions of Companies Act, the company is also under an
obligation to redress all investor complaints in terms of the advice/directions of SEBI, in view
of the provisions of section 11 of the SEBI Act. However, the company has not shown any
tenacity in resolving the investor grievances and in spite of repeated advice of SEBI, the said
investor grievances are pending till date.
10. Failure to redress investor grievances, by a listed company adversely affects the confidence of
investors in the securities market. In view of the foregoing, I am of the view that it is a fit case
to issue appropriate directions under section 11B of the SEBI Act against the company as
contemplated in the show cause notice issued to it. I, therefore, in exercise of the powers
conferred upon me under section 19 of the SEBI Act read with sections 11 and 11B thereof,
hereby restrain and prohibit Stellar Drug Limited from accessing the securities market and
from buying, selling or dealing in securities, directly or indirectly, in whatsoever manner, till it
obtains SCORES authentication in terms of the SEBI circular dated August 13, 2012 and
resolves all the investor grievances pending against it. The aforesaid direction is without
prejudice to any other action that may be taken against the company and its directors in
accordance with law.
11. This Order shall come into force with immediate effect. A copy of this Order shall also be
served upon the depositories and stock exchanges for necessary action.
______________________________________________________________________________
In the matter of Stellar Drugs Limited
Page 3 of 3